1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Burden of established cardiovascular disease in people with type 2 diabetes and matched controls : Hospital-based care, days absent from work, costs and mortality
(
- Contribution to journal › Article
- 2022
-
Mark
Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
2022) In Diabetes, Obesity and Metabolism(
- Contribution to journal › Article
- 2020
-
Mark
Costs of diabetes complications : hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden
(
- Contribution to journal › Article
-
Mark
Days absent from work as a result of complications associated with type 2 diabetes : Evidence from 20 years of linked national registry data in Sweden
(
- Contribution to journal › Article
-
Mark
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective
(
- Contribution to journal › Article
- 2017
-
Mark
Diabetes mellitus typ 1
2017)(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Diabetes mellitus typ 2.
2017)(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2015
-
Mark
Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study.
(
- Contribution to journal › Article
- 2014
-
Mark
Sialic acid and incidence of hospitalization for diabetes and its complications during 40-years of follow-up in a large cohort: The Värmland survey.
(
- Contribution to journal › Article
- 2012
-
Mark
Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction
(
- Contribution to journal › Article